Behavioral therapy provides depression and adherence benefits in HIV study

Four months of cognitive behavioral therapy for depression and antiretroviral adherence significantly improved adherence and depression scores when compared with treatment as usual in a three-way randomized trial involving adults with HIV infection. Relative improvements in adherence and depression held up in the eight months ...

November 29, 2016
EATG  News  

Injections, implants tested as new weapons to prevent HIV

Scientists are taking the battle to prevent HIV to the next level with large-scale trials set to start using injections to protect vulnerable groups such as gay men and women in Africa for at least two months. Further down the road, the hope is to produce ...

November 29, 2016
EATG  News  

WHO issues new guidance on HIV self-testing

29 November 2016 | GENEVA – In advance of World AIDS Day, WHO has released new guidelines on HIV self-testing to improve access to and uptake of HIV diagnosis. According to a new WHO progress report lack of an HIV diagnosis is a major obstacle to ...

November 29, 2016
EATG  EATG  News  

Health agencies should challenge the idea that most gay men use drugs

Drug use generally and chemsex more specifically are perceived to be common and normalised behaviours among gay men involved in those scenes in London, but this perception is contradicted by survey data. As social norms influence health-related behaviour, health promotion interventions should challenge the idea ...

November 29, 2016
EATG  News  

Hepatitis C sheds enough in the rectum to transmit through anal sex

Researchers have come up with the first direct evidence that enough hepatitis C virus (HCV) sheds into the rectums of HIV-positive men who have sex with men (MSM) to transmit directly to another man’s penis during anal sex, even when no blood is present. Publishing their ...

November 29, 2016
EATG  News  

First new HIV vaccine efficacy study in seven years has begun

South Africa hosts historic NIH-supported clinical trial The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The study, called HVTN 702, involves a new version of the ...

November 28, 2016
EATG  News  

Investment in effective prevention

Strengthened global political commitment to HIV prevention must be followed by strengthened financial commitment. The successes of the global AIDS response to date have been fuelled by extraordinary investment. The total amount of financial resources for AIDS responses in low- and middle-income countries reached an ...

November 28, 2016
EATG  News  

ECDC HIV testing guidance evaluation technical report

Getting ready for World AIDS Day, the European Centre for Disease Prevention and Control (ECDC) has published the HIV testing guidance evaluation technical report, now released on ECDC website ahead of December 1st: http://ecdc.europa.eu/en/publications/Publications/HIV-testing-guidance-evaluation.pdf This document was developed with considerable input from members of the PLHIV ...

November 26, 2016
EATG  News  

Non-adherence most important risk factor for sofosbuvir/ledipasvir failure

Research carried out by Mount Sinai Medical Center, New York, found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni). The main reasons cited for non-adherence were failing to take medication as prescribed and hospitalisation. The findings were presented at ...

November 25, 2016
EATG  News  

World AIDS Day message 2016

1 December 2016 Michel Sidibé, Executive Director of UNAIDS, Under-Secretary-General of the United Nations Today, we commemorate World AIDS Day—we stand in solidarity with the 78 million people who have become infected with HIV and remember the 35 million who have died from AIDS-related illnesses since the ...

November 25, 2016
EATG  News  

Rosuvastatin slows subclinical atherosclerosis in HIV group with normal LDL-cholesterol

Rosuvastatin for 96 weeks significantly slowed progression of subclinical atherosclerosis — as measured by common carotid artery intima-media thickness (CCA-IMT) — in a double-blind placebo-controlled trial. Participants had normal low-density lipoprotein cholesterol (LDL-C) before treatment began, but the statin further lowered LDL-C, according to the ...

November 24, 2016
EATG  News